Boston Scientific Corporation (BSX) Receives Price Target

Boston Scientific Corporation (BSX) : The highest level Boston Scientific Corporation (BSX) is projected to reach is $30 for the short term and the lowest estimate is at $20. The consolidated price target from 18 rating analysts who initiate coverage on the stock is $26.08 and the possibility the share price can swing is $2.99.

Boston Scientific Corporation (BSX) : Zacks Investment Research ranks Boston Scientific Corporation (BSX) as 3, which is a Hold recommendation. 11 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 3 other analysts are mildly bullish on the stock and favor a Buy. A total of 4 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 18 research analysts is 1.58, which indicates as a Buy.


Also, In a research note released to the investors, Citigroup maintains its rating on Boston Scientific Corporation (NYSE:BSX).The analysts at the brokerage house have a current rating of Buy on the shares. In a recent information released to the investors, Citigroup raises the new price target from $26 per share to $28 per share. The rating by the firm was issued on August 3, 2016.

Boston Scientific Corporation (NYSE:BSX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $24.07 and $23.85 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $24.35. The buying momentum continued till the end and the stock did not give up its gains. It closed at $24.33, notching a gain of 2.14% for the day. The total traded volume was 9,115,567 . The stock had closed at $23.82 on the previous day.

Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.